Money and murder: the dark side of the Asilomar meeting on recombinant DNA
By Matthew Cobb,
Nature
| 02. 17. 2025
On 24 February 1975, some 150 people met at the Asilomar Conference Grounds near Monterey on the Californian coast. They were mostly scientists from the United States, together with representatives of various companies and government agencies, and 16 journalists. Their subject was the new technology of recombinant DNA — molecules created in a laboratory by stitching together genetic material from different organisms. Researchers were excited by the possibilities for discoveries, and the potential of the technique to produce drugs, for example using specially engineered bacteria to make insulin. But they were also terrified that they might inadvertently create diseases that could infect lab workers and the wider community.
By the end of the meeting, its participants had agreed to adopt biosafety protocols that are still in force in the United States, and which have hugely influenced similar regulations worldwide. The meeting has become known simply as Asilomar, a byword for how a scientific community came together to forge consensus on a thorny topic. It is often held up as an example of how science can self-regulate without the involvement of...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...